Imbed Biosciences Advanced Wound Care Portfolio Highlighted SAWC Spring 2017
Madison, WI, April 4, 2017 – Imbed Biosciences, a developer of advanced biomaterials and wound care devices, announced today that the company will present new data and information featuring its MicroLyte™ antimicrobial and antibiofilm wound dressings at the Spring Symposium on Advanced Wound Care (SAWC) in San Diego, CA from April 5-8, 2017. The company will also have a presence in the exhibitor space at booth #1110. SAWC is the nation’s largest interdisciplinary wound care forum.
The company’s poster presentations will highlight research conducted by multi-disciplinary teams internal to Imbed Biosciences, as well as at the University of Wisconsin-Madison, the University of California-Davis, and Mission Hospital (Asheville, NC) including recent clinical outcomes using the company’s breakthrough MicroLyte™ Ag antimicrobial wound dressing on complex chronic wounds. The study is ongoing and involves 100 patients at Mission Hospital with a variety of complex chronic wounds. Imbed will also present veterinary case study outcomes as well as development of a dressing which can reliably eradicate an established biofilm in a wound bed and thus be used in an infected wound.
“The work that will be presented at SAWC represents a wide range of our current research and commercial activities. Meeting attendees will see clinical outcomes in both human and veterinary patients along with results from our early development work on a next generation antibiofilm product,” said Ankit Agarwal, President and CEO of Imbed Biosciences.
Additionally, prospective users will get a first-look at Imbed’s groundbreaking, FDA-cleared MicroLyte™ Ag ultrathin, antimicrobial wound dressing. MicroLyte™ Ag has only a fraction of the silver of competitive dressings, leading to lower incidences of tissue staining and toxicity while still maintaining high antimicrobial activity. FDA cleared MicroLyte™ Ag for use for up to three days in acute wounds such as, lacerations, skin tears, abrasions, surgical wounds (donor and graft sites, incisions), partial thickness first and second degree burns, and partial to full-thickness dermal ulcers such as, diabetic, decubitus, venous stasis, arterial stasis ulcers.
Poster presentations of interest include:
Ultrathin Hydrogel Dressings Containing Gallium Ions and Silver Nanoparticles for the Elimination of Biofilms
G. Pranami1, T. B. Nelson1, E. C. Crawford1, J. L. Dalsin1, M. H. Herron2, C. J. Czuprunski3, N. L. Abbott2, A. Agarwal1,2
1Imbed Biosciences Inc., Madison, WI, USA; 2Department of Chemical Engineering, University of Wisconsin-Madison; 3School Of Veterinary Medicine, University of Wisconsin-Madison
Use of an antimicrobial microfilm wound dressing in spontaneous wounds in animals
Jonathan F. McAnulty, DVM, PhD1 and Michael J. Schurr, MD2
1Department of Surgical Sciences, University of Wisconsin – Madison, WI; 2Mission Hospital, Asheville, NC
Ultrathin Dissolvable Antimicrobial Wound Dressing Is Safe and Effective In Patients With Complex Chronic Wounds
David Humphrey, MD1, Michael J. Schurr, MD2, William Shillinglaw MD1
1Mission Hospital, Asheville NC; 2MAHEC Department of Surgery, Asheville, NC
About Imbed Biosciences, Inc.
Imbed Biosciences is a privately held medical device company developing next-generation medical devices for the management of burns, chronic ulcers, gastro-intestinal defects, and tissue repair. Company has a portfolio of products in development based on its patented polymeric Microfilm™ platform that present bioactive molecules on tissue surfaces to manage wound infections, biofilms, and local pain and support wound healing. Imbed is backed by venture capital group WISC Partners based in Madison, WI. Company has also received research grants from National Institutes of Health and National Science Foundation. For more information, visit www.www.imbedbio.com and follow facebook.com/imbedbio and @imbedbio on twitter.